Tumor genomic typing of NSCLC is important before starting the ICI therapy, not only because ICIs have no or inferior clinical effect in oncogene driven tumors, but because they have also been associated with increased incidence and severity of interstitial lung disease and other ICI-related toxicities when they are in sequential or concurrent use with EGFR TKIs in patients with metastatic NSCLC [13, 14]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.